C
Celularity Inc. (CELU)
NCM – Real vaqt narxi. Valyuta: USD
0.78
+0.01 (0.84%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
0.78
+0.01 (0.84%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Celularity Inc., regenerativ va hujayrali tibbiyot kompaniyasi, qarish bilan bog'liq va degenerativ kasalliklarni davolashga qaratilgan. U diabetik oyoq yarasi va Kron kasalligi uchun mezenximaga o'xshash yopishqoq stromal hujayralarni o'z ichiga olgan, tayyor plazentadan olingan allogenik hujayrali terapiya mahsulot nomzodlarini ishlab chiqadi. Kompaniya uchta segment orqali ishlaydi: Hujayrali terapiya, Degenerativ kasalliklar va BioBanking. Uning terapevtik dasturlari orasida otoimmün (Kron) va degenerativ kasalliklarni davolash uchun PDA-001; va faskapulohumeral mushak distrofiyasini davolash uchun PDA-002 mavjud. Kompaniya, shuningdek, osteoartritni davolash uchun insonning tug'ruqdan keyingi plazentadan olingan ekzom mahsuloti bo'lgan pExo-001ni ishlab chiqmoqda. Bundan tashqari, u Biovance, Biovance 3L, Rebound, Interfyl va Centaflex kabi jarrohlik va yaralarni davolash bozorlarida ishlatiladigan mahsulotlarni ishlab chiqaradi, sotadi va litsenziyalaydi; va LifebankUSA brendi ostida to'liq muddatli homiladorliklardan keyin kindik qoni va platsenta qoni va to'qimalarini yig'adi, qayta ishlaydi va saqlaydi. Celularity Inc. Sorrento Therapeutics, Inc. bilan litsenziyalangan CD19 CAR-T mahsulotlarini ishlab chiqish va tijoratlashtirish bo'yicha litsenziyalash shartnomasiga ega; va Regeneron Pharmaceuticals, Inc. bilan allogenik hujayrali terapiya nomzodlarini tadqiq qilishni qo'llab-quvvatlash uchun tadqiqot hamkorligi xizmatlari shartnomasiga ega. Celularity Inc. 1998 yilda tashkil etilgan va Florham Park, Nyu-Jersi shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Robert Joseph Hariri M.D., Ph.D. | Founder, CEO & Chairman |
| John Sprague | Acting Chief Financial Officer |
| Mr. Carlos Ramirez | SVP of Investor Relations |
| Mr. David Jakob Lemus CPA, M.S., MBA | Treasurer |
| Mr. Tim Wilk | Senior Vice President of Technical Operations |
| Sharmila Koppisetti M.D. | Senior Vice President of Clinical Dev. Immunology & Drug Safety |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | 10-K | form10-k.htm |
| 2026-04-21 | 8-K | form8-k.htm |
| 2026-03-31 | NT 10-K | formnt10-k.htm |
| 2026-03-10 | 8-K | form8-k.htm |
| 2026-03-05 | 8-K | form8-k.htm |
| 2026-01-21 | 8-K | form8-k.htm |
| 2026-01-05 | CORRESP | filename1.htm |
| 2025-12-31 | S-1 | forms-1.htm |
| 2025-12-23 | 8-K | form8-k.htm |
| 2025-12-19 | 8-K | form8-k.htm |